dc.contributor.author | Browning, Michael | |
dc.date.accessioned | 2021-01-05T18:37:30Z | |
dc.date.available | 2021-01-05T18:37:30Z | |
dc.date.issued | 2017-02 | |
dc.identifier.citation | Browning, M., 2017. Symptom trajectories in discontinuation trials. Lancet Psychiatry 4, 176–178 | en |
dc.identifier.issn | 2215-0366 | |
dc.identifier.uri | https://oxfordhealth-nhs.archive.knowledgearc.net/handle/123456789/702 | |
dc.description.abstract | Many patients with clinical depression, particularly those with recurrent illness, are treated with maintenance antidepressants after an acute-phase response. But how effective is this approach? The effectiveness of maintenance treatment is most commonly tested in trials with a discontinuation design, 1 in which patients who have already responded to a treatment are randomly assigned to either ongoing treatment or placebo. Such studies provide a measure of the benefit of maintenance treatment over discontinuation. However, discontinuation studies have several limitations. The first is common to psychiatric treatment studies generally; how and when should we assess whether a patient's symptoms have changed after discontinuation? The second is more specific to discontinuation designs; the selection of patients based on a positive response to that treatment is likely to inflate the apparent beneficial effect of the treatment, because that subgroup of patients has the most to lose from stopping treatment. | en |
dc.description.uri | https://doi.org/10.1016/S2215-0366(17)30054-8 | en |
dc.language.iso | en | en |
dc.subject | Depressive Disorders | en |
dc.subject | Antidepressant Drugs | en |
dc.title | Symptom trajectories in discontinuation trials. | en |
dc.type | Article | en |